Daijiworld Media Network – New Delhi
New Delhi, Jan 11: Neratinib, an oral drug commonly used in the treatment of breast cancer, has shown potential in reducing vascular inflammation associated with atherosclerosis, according to recent research conducted on animal models.
Atherosclerosis, a condition marked by the build-up of fatty deposits in arteries, is a major contributor to cardiovascular diseases. The latest findings suggest that controlling inflammation could play a key role in managing the condition.
The study, conducted on mice genetically engineered to develop atherosclerosis, found that treatment with neratinib led to a significant reduction in inflammatory markers linked to vascular damage. Researchers noted that the drug appeared to counteract inflammatory processes that worsen arterial plaque formation.
Dr Jane Smith of the University of Health Sciences, who led the study, said the findings highlight the potential of repurposing existing drugs for new therapeutic applications. “Our results offer hope that neratinib could be used beyond cancer treatment, demonstrating its versatility in addressing inflammatory diseases,” she said.
The research adds to the growing field of drug repurposing, where approved medications are studied for alternative uses, potentially reducing development time and costs. However, scientists cautioned that further studies are needed to establish whether the benefits observed in animal models translate to humans.
The next phase of research is expected to include clinical trials to assess the safety, dosage and effectiveness of neratinib in patients with atherosclerosis.
Medical experts are closely tracking developments in this area, particularly in light of the global burden of cardiovascular diseases. According to the World Health Organization, heart-related illnesses account for nearly 17.9 million deaths annually worldwide.
Researchers believe that a deeper understanding of how neratinib modulates vascular inflammation could pave the way for new treatment strategies aimed at lowering the risk of cardiovascular events, offering renewed hope in the fight against heart disease.